In the phase I AURA study assessing safety, tolerability, and efficacy of osimertinib in EGFR mutant NSCLC progressive under EGFR-TKIs, plasma p.T790M genotyping in 237 patients revealed 70% sensitivity and 69% specificity. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.